Literature DB >> 3280812

Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors.

N B Shulman.   

Abstract

The prevalence of hypertension and the incidence of complications from uncontrolled elevated blood pressure in blacks is much greater than in the white population. In general, blacks have underlying differences in the factors relating to blood pressure level, including low plasma renin, and, in certain instances, a decreased ability to excrete sodium. The stepped-care approach in the management of the black hypertensive patient is similar to that taken with white patients, but racial differences in response to antihypertensive drugs exist that require careful consideration when choosing a treatment regimen. Thiazide diuretics are effective in blacks and are often used as initial therapy. Blacks tend to respond less well to β-blockers, but when combined with a diuretic, they are also effective. Encouraging data are available on the use of calcium channel blockers in blacks. When combined with a diuretic, the angiotensin-converting enzyme (ACE) inhibitors also provide an alternative to therapy for black patients. The use of low doses of ACE inhibitors has reduced the high incidence of adverse effects associated with this group of drugs in earlier studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280812      PMCID: PMC2625639     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  27 in total

1.  The role of renal hemodynamics in the antihypertensive effect of captopril.

Authors:  K Ando; T Fujita; Y Ito; H Noda; K Yamashita
Journal:  Am Heart J       Date:  1986-02       Impact factor: 4.749

2.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1984-05

Review 3.  Angiotensin-converting enzyme inhibitors: past, present, and bright future.

Authors:  C R Edwards; P L Padfield
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

4.  Propranolol versus labetalol: interesting differences in efficacy.

Authors:  W Flamenbaum
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

Review 5.  Review of the overall experience of captopril in hypertension.

Authors:  E D Frohlich; R A Cooper; E J Lewis
Journal:  Arch Intern Med       Date:  1984-07

6.  Latest guidelines on the treatment of high blood pressure.

Authors:  G E Thomson
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

7.  Captopril in hypertension; seven years later.

Authors:  A C Jenkins; G R Dreslinski; S S Tadros; J T Groel; R Fand; S A Herczeg
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

8.  Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension.

Authors:  P A Freier; G L Wollam; W D Hall; D J Unger; M B Douglas; R P Bain
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

9.  Blood volume expansion among blacks: an hypothesis.

Authors:  J Schachter; L H Kuller
Journal:  Med Hypotheses       Date:  1984-05       Impact factor: 1.538

10.  Comparison of the effectiveness of a beta blocker (atenolol) and a diuretic (chlorthalidone) in black hypertensive patients.

Authors:  G A Grell; T E Forrester; G A Alleyne
Journal:  South Med J       Date:  1984-12       Impact factor: 0.954

View more
  1 in total

1.  Comparison of Risk of Atrial Fibrillation in Black Versus White Patients After Coronary Artery Bypass Grafting.

Authors:  Jimmy T Efird; Preeti Gudimella; Wesley T O'Neal; William F Griffin; Hope Landrine; Linda C Kindell; Stephen W Davies; Daniel F Sarpong; Jason B O'Neal; Patricia Crane; Margaret A Nelson; Thomas Bruce Ferguson; Walter Randolph Chitwood; Alan P Kypson; Ethan J Anderson
Journal:  Am J Cardiol       Date:  2016-01-15       Impact factor: 2.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.